Renal function at two years in liver transplant patients receiving everolimus: Results of a randomized, multicenter study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F13%3A00058813" target="_blank" >RIV/00023001:_____/13:00058813 - isvavai.cz</a>

Výsledek na webu

<a href="http://onlinelibrary.wiley.com/doi/10.1111/ajt.12280/pdf" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/ajt.12280/pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ajt.12280" target="_blank" >10.1111/ajt.12280</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Renal function at two years in liver transplant patients receiving everolimus: Results of a randomized, multicenter study

Popis výsledku v původním jazyce

In a 24-month prospective, randomized, multicenter, open-label study, de novo liver transplant patients were randomized at 30 days to everolimus (EVR)+Reduced tacrolimus (TAC; n=245), TAC Control (n=243) or TAC Elimination (n=231). Randomization to TAC Elimination was stopped prematurely due to a significantly higher rate of treated biopsy-proven acute rejection (tBPAR). The incidence of the primary efficacy endpoint, composite efficacy failure rate of tBPAR, graft loss or death postrandomization was similar with EVR+Reduced TAC (10.3%) or TAC Control (12.5%) at month 24 (difference -2.2%, 97.5% confidence interval [CI] -8.8%, 4.4%). BPAR was less frequent in the EVR+Reduced TAC group (6.1% vs. 13.3% in TAC Control, p=0.010). Adjusted change in estimated glomerular filtration rate (eGFR) from randomization to month 24 was superior with EVR+Reduced TAC versus TAC Control: difference 6.7mL/min/1.73m2 (97.5% CI 1.9, 11.4mL/min/1.73m2, p=0.002). Among patients who remained on treatment, me

Název v anglickém jazyce

Renal function at two years in liver transplant patients receiving everolimus: Results of a randomized, multicenter study

Popis výsledku anglicky

In a 24-month prospective, randomized, multicenter, open-label study, de novo liver transplant patients were randomized at 30 days to everolimus (EVR)+Reduced tacrolimus (TAC; n=245), TAC Control (n=243) or TAC Elimination (n=231). Randomization to TAC Elimination was stopped prematurely due to a significantly higher rate of treated biopsy-proven acute rejection (tBPAR). The incidence of the primary efficacy endpoint, composite efficacy failure rate of tBPAR, graft loss or death postrandomization was similar with EVR+Reduced TAC (10.3%) or TAC Control (12.5%) at month 24 (difference -2.2%, 97.5% confidence interval [CI] -8.8%, 4.4%). BPAR was less frequent in the EVR+Reduced TAC group (6.1% vs. 13.3% in TAC Control, p=0.010). Adjusted change in estimated glomerular filtration rate (eGFR) from randomization to month 24 was superior with EVR+Reduced TAC versus TAC Control: difference 6.7mL/min/1.73m2 (97.5% CI 1.9, 11.4mL/min/1.73m2, p=0.002). Among patients who remained on treatment, me

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FJ - Chirurgie včetně transplantologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American journal of transplantation

ISSN

1600-6135

e-ISSN

—

Svazek periodika

13

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

1734-1745

Kód UT WoS článku

000320928800017

EID výsledku v databázi Scopus

—